Production of an appropriate number of distinct cell types in precise locations during embryonic development is critical for proper tissue function. Homeostatic renewal or repair of damaged tissues in adults also requires cell expansion and transdifferentiation to replenish lost cells. However, the responses of diverse cell types to tissue injury are not fully elucidated. Moreover, the molecular mechanisms underlying transdifferentiation remain poorly understood. This knowledge is essential for harnessing the regenerative potential of individual cell types. This study investigated the fate of pulmonary neuroendocrine cells (PNECs) following lung damage to understand their plasticity and potential. PNECs are proposed to carry out diverse physiological functions in the lung and can also be the cells of origin of human small cell lung cancer. We found that Notch signaling is activated in proliferating PNECs in response to epithelial injury. Forced induction of high levels of Notch signaling in PNECs in conjunction with lung injury results in extensive proliferation and transdifferentiation of PNECs toward the fate of club cells, ciliated cells and goblet cells. Conversely, inactivating Notch signaling in PNECs abolishes their ability to switch cell fate following lung insult. We also established a connection between PNEC transdifferentiation and epigenetic modification mediated by the polycomb repressive complex 2 and inflammatory responses that involve the IL6-STAT3 pathway. These studies not only reveal a major pathway that controls PNEC fate change following lung injury but also provide tools to uncover the molecular basis of cell proliferation and fate determination in response to lung injury. STEM CELLS 2018;36:377-391
INTRODUCTION
How distinct cell fates are determined is a fundamental issue that has been actively pursued [1] . Discovery of genes and pathways that are involved in cell fate decision during lung development has enhanced our knowledge of how na€ ıve progenitors progress to differentiated lung cell types although significant gaps in our mechanistic understanding of this process remain. Lungs display remarkable regenerative/repair capacity following various insults and injuries to this organ [2, 3] . In this course, expansion and transdifferentiation of lung cells is an essential mechanism for producing a proper number of lung cell types required for repairing damaged airway epithelium or mesenchyme. However, the potentials and limitations of fate conversion for different cell types during homeostasis and following lung damage have not been clarified. Signaling pathways used during embryonic lung development seem to be redeployed for lung repair. Thus, studying how signaling pathways control cell fate during lung repair will not only reveal its molecular basis but will also provide insight into the connections between development and regeneration/ repair.
PNECs comprise a unique population in the lung [4] . While PNECs are relatively rare, the various amines and peptides secreted by PNECs have been implicated in diverse physiological and pathological processes in the lung. For instance, PNECs have been proposed to regulate lung development, function in airway oxygen sensing, regulate pulmonary blood flow, control bronchial tonus, modulate immune responses, and maintain a stem cell niche [4, 5] . Nevertheless, in vivo validation of PNEC activity in lung development and homeostasis [6] is largely lacking. Given the evolutionary conservation of PNECs in diverse species, they likely execute essential physiological functions. Genetic and molecular studies in animals will be critical in revealing PNEC activities in a physiological setting. PNECs are also relevant to human diseases. PNECs are associated with human small cell lung cancer (SCLC), many of which express PNEC markers. Importantly, mouse models of human SCLC provide strong evidence to support a model in which SCLC can originate from PNECs [7] [8] [9] . A basic understanding of PNEC potentials during homeostasis and repair will yield insight into PNEC transformation and progression. These investigations will also increase our knowledge of how breakdown of normal homeostasis leads to diseased states.
In earlier work, we showed that PNECs proliferated in response to naphthalene-induced lung injury and a fraction of proliferating PNECs generated club (Clara) cells and ciliated cells [8] . The molecular mechanisms that control PNEC transdifferentiation are unknown. We set out to investigate the signals that are involved in fate change of PNECs following lung injury. Our findings identify Notch signaling as a key pathway that controls PNEC fate change in response to lung damage. We also uncover epigenetic changes and inflammatory responses that could interact with Notch signaling during lung injury/repair. These results establish the foundation for mechanistic studies to uncover a signaling network that executes the selection of a particular cell fate. [8] . The Institutional Animal Care and Use Committee at Zhejiang University and the University of California, San Francisco, approved all experiments performed in this study.
MATERIALS AND METHODS

Animal Husbandry
Mouse Models of Lung Injury
Tamoxifen (TM) injection and naphthalene-induced lung injury have been previously described [8] . Except for studies on TM washout time, mice were first injected with TM every other day three times; naphthalene was administered 4 weeks after the last dose of TM. Lungs were collected from mice at different time points after naphthalene administration (e.g., 1, 2, 3, 7, 14, 21, 28, and 56 days).
EZH2 Inhibition in Mice
EPZ-6438 was purchased from Selleck Chemicals (Houston, TX, USA) (Cat# S7128) and formulated in 0.5% NaCMC w/0.1% Tween-80 in water. Mice were given EPZ-6438 (300 mg/kg) or vehicle control once daily by oral gavage.
Immunofluorescence and Immunohistochemistry
Dissected mouse lungs were fixed in 4% paraformaldehyde in PBS for 1 to 2 hours at 48C. Lungs were embedded in paraffin wax and sectioned at 6 lm or embedded in OCT and sectioned at 10 lm. Histological analysis was performed as reported [8, 10] .
Histology and immunohistochemistry were performed following standard procedures. The following primary antibodies were used: mouse anti-p63 (1:100; Santa Cruz Biotechnology Secondary antibodies and conjugates used were donkey anti-chick DyLight 488 (Jackson ImmunoResearch Laboratories (West Grove, PA, USA)), donkey anti-rabbit Alexa Fluor 488 or 594 (1:1,000; Life Technologies), donkey anti-goat Alexa Fluor 488, 594, or 647 (1:1,000; Life Technologies), donkey antimouse Alexa Fluor 594 (1:1,000; Life Technologies), and DAPI (1:10,000; Sigma-Aldrich).
For biotinylated secondary antibodies (donkey anti-rabbit, 1:1,000; donkey anti-goat, 1:1,000; and horse anti-mouse, 1:1,000; Jackson ImmunoResearch Laboratories), the signal was detected using HRP-conjugated streptavidin (1:1,000; Perkin-Elmer (Boston, MA, USA)) in combination with fluorogenic substrate Alexa Fluor 594 tyramide (1:200, TSA kit; Perkin-Elmer). ; ROSA26 NICD/mTmG mice were analyzed for lung marker expression at each time point (3 days, 1 week, 2 weeks, 3 weeks, 4 weeks, and 8 weeks post-naphthalene). Cells were manually counted based on immunofluorescence staining of lung cell markers. Independent slides were picked randomly for the analysis. The results were presented as mean 6 SEM.
Quantitative Polymerase Chain Reaction (qPCR) Analysis
The following primers for mouse genes were used: Il1b (forward, 5
0 -TGGACCTTCCAGGATGAGGACA-3 0 ; reverse, 5
Cell Lines
Human SCLC cell line NCI-H69 and mouse SCLC cells derived from p53/Rb/Pten-deficient lung tumors induced by CGRP CreER as described previously [8] were maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum (Life Technologies), penicillin/streptomycin (Life Technologies), and L-glutamate (Life Technologies).
Western Blot Analysis
After treatment with EPZ-6438 at 0.5 lM for 48 hours, mouse SCLC cells were harvested and lysed in RIPA buffer (50 mM Tris-Cl at pH 7.5, 150 mM NaCl, 5mM EDTA, 1% Triton X-100, 0.1% SDS, 1% Na deoxycholate, protease inhibitors). Similarly, lung lobes were homogenized in RIPA buffer. Lysates were resolved on 10% SDS-PAGE gels and transferred to PVDF membranes following standard procedures of Western blot analysis. Chemiluminescent detection was performed using ECL Plus detection reagents (GE Healthcare Life Sciences (Pittsburgh, PA, USA)). The following primary antibodies were used: rabbit anti-H3K27me3 ( 
RESULTS
Transdifferentiation of Pulmonary Neuroendocrine Cells Following Lung Injury Is Unaffected by the Tamoxifen Washout Period
We previously reported the ability of PNECs to transdifferentiate into club cells and ciliated cells following naphthaleneinduced lung injury [8] . This was conducted on CGRP CreER/1 ; ROSA26 mTmG/1 mice in which TM injection activated CreER from the neuroendocrine cell-specific Calca promoter. CreER encodes a fusion protein of Cre recombinase and estrogen receptor (ER) and becomes active when TM is present [11] . Active CreER induced GFP expression from the ROSA26 mTmG locus [12] and labeled most, if not all, PNECs for fate mapping. The TM washout period in our original report was 24 hours [8] . It has recently been suggested that the TM washout period could be important in interpreting the results of fate change following lung injury [13] . One possible caveat to our conclusion of PNEC transdifferentiation is that some injured club cells may activate the Calca promoter and induce CreER expression. If residual TM was present due to an insufficient washout period, it would activate CreER and subsequently a GFP reporter in these injured club cells. In this scenario, lineage-labeled club cells would be misinterpreted as transdifferentiated cells originating from PNECs.
To exclude this possibility, we repeated naphthaleneinduced lung injury using CGRP CreER/1 ; ROSA26 mTmG/1 mice that had received TM. We tested various TM washout periods, including 3 days, 2 weeks, 1 month, and 2 months. No apparent difference in the distribution of GFP-labeled club cells and ciliated cells was found using different TM washout periods (Supporting Information Fig. S1 ). Transdifferentiation of PNECs into club cells and ciliated cells was further confirmed using Ascl1
CreER/1 ; ROSA26 mTmG/1 mice in which CreER produced from the promoter of Ascl1 [14] , the master regulator of PNEC generation, enabled lineage tracing of labeled PNECs (Supporting Information Fig. S1 ). We thus validated our conclusion that PNECs possess the capability of transdifferentiating into club cells and ciliated cells following lung injury. identify the signaling pathways that impact PNECs in this process. Previous studies suggest that Notch signaling promotes differentiation toward the club cell fate while inhibiting the production of PNECs and ciliated cells during development [15] [16] [17] [18] [19] . In addition, high levels of Notch activity appear to drive goblet cell identity at the expense of ciliated cells during lung development [20] . Thus, the Notch pathway is a particularly attractive candidate for controlling PNEC transdifferentiation following lung injury. To test this idea, we first asked whether the Notch pathway is activated in PNECs following lung injury. We used CGRP CreER/1
Notch Signaling Is Activated in Pulmonary Neuroendocrine Cells in Response to Lung Injury
; ROSA26 mTmG/1 mice in which TM injection led to GFP-labeling of PNECs to probe the state of Notch pathway activation in PNECs in response to epithelial injury induced by naphthalene. Ligand-receptor interactions trigger a sequence of proteolytic events of the Notch receptor, leading to the production of the Notch intracellular domain (NICD). NICD enters the nucleus to activate the Notch pathway by binding to RBPJ (recombination signal binding protein for immunoglobulin kappa J region) and replacing a corepressor complex with a coactivator complex for Notch target gene expression [21] . Thus, the presence of nuclear NICD is indicative of Notch pathway activation. We found that NICD immunoreactivity (for cleaved Notch 1) was absent in PNECs during normal homeostasis ( Fig. 1A-1D ) and Notch targets, such as HES1, were not induced in PNECs (Fig.  1E-1H ). However, nuclear NICD appeared in a subset (7%) of GFP-labeled PNECs approximately 3 days after naphthalene-induced lung injury ( Fig. 1I-1L ), concomitant with HES1 induction (Fig. 1M-1P ). Barely any nuclear NICD was detected in PNECs prior to this time point. The percentage of GFP 1 NICD 1 to GFP 1 cells increased with time (18% at 5 days post-naphthalene treatment). These findings support our hypothesis in which Notch pathway activation is a key event in PNEC transdifferentiation following lung injury.
High Levels of Notch Pathway Activation in Pulmonary Neuroendocrine Cells Lead to Their Extensive Expansion following Lung Injury
To examine whether Notch signaling can promote PNEC transdifferentiation, we induced uniform, high levels of Notch pathway activity in PNECs prior to lung injury. We generated CGRP CreER/1 ; ROSA26 NICD-IRES-GFP/lacZ mice, which carry one copy of the ROSA26 NICD-IRES-GFP [22] and ROSA26 lacZ [R26R] [23] alleles, and administered TM to these mice. For simplicity, the ROSA26 NICD-IRES-GFP allele will be abbreviated as ROSA26 NICD in this study. In naphthalene-induced lung injury models, CGRP CreER/1 ; ROSA26 NICD/lacZ mice were injected with TM and naphthalene sequentially. PNECs in which CreER was activated by TM would induce NICD expression (from the ROSA26 NICD allele) and activate the Notch pathway. PNECs were also lineage labeled by b-galactosidase (lacZ) (from the ROSA26 lacZ [R26R] allele). We found that Notch pathway activation in CGRP CreER/1 ; ROSA26 NICD/lacZ mice by TM injection induced massive expansion of PNECs following naphthalene-induced lung injury ( Fig.  1Q-1X ). LacZ-labeled cells that originated from PNECs became a dominant cell population of the airway epithelium and in many airways they constituted almost 50% of the lung epithelium (Fig. 1Q, 1U, 1V ). By contrast, a small number of lacZlabeled clusters were found in CGRP CreER/1 ; ROSA26 lacZ/1 mice following TM injection and naphthalene-induced lung injury (Fig. 1R, 1W, 1X ). In the absence of lung injury, lacZlabeled clusters were barely detectable by whole-mount staining (Fig. 1S) . No lacZ-positive cells were found in the absence of TM (Fig. 1T ). This suggests that PNECs underwent substantial expansion following a combination of Notch activation and lung injury. During lung development, ASCL1 is critical for PNEC differentiation and PNECs failed to be generated in Ascl1 null mice [24] . Loss of ASCL1 in CGRP CreER/1 ; ROSA26 NICD/mTmG ( Fig. 2E-2H ) occurred at a faster rate than the disappearance of other PNEC markers (Supporting Information Fig. S2 ). We speculate that reduction in ASCL1 levels represents a critical step of PNEC transdifferentiation. We further tested the effect of NICD on Ascl1 expression in vitro using NCI-H69 cells derived from human SCLC. We observed a significant reduction of endogenous ASCL1 in NCI-H69 cells that overexpressed NICD by immunofluorescence (Supporting Information Fig. S2 ). Reduction of ASCL1 by NICD was further confirmed by Western blot analysis (data not shown). We also examined the mRNA levels of differentiation markers in NICD-overexpressing NCI-H69 cells. Interestingly, mRNA expression of both CC10 and Muc5AC was increased as a result of NICD expression (Supporting Information Fig. S2 ). In particular, CC10 mRNA levels were elevated by several hundred-fold. Activation of the Notch pathway by NICD overexpression was confirmed by expression of downstream targets such as Hes1 and Hes5 (Supporting Information Fig. S2 ). These findings support previous reports in which Notch pathway activation was capable of downregulating ASCL1 levels in cell lines [25] . However, regulation of Ascl1 levels in vivo is likely more complex. We also tested a battery of other established lung cell type markers, including CC10 (Clara [club] cell marker), acetylated [Ac]-tubulin (ciliated cell marker), and Muc5AC (goblet cell marker) at 3 days post-lung injury ( Figs. 2A-2D ; ROSA26 NICD/mTmG lungs (Fig. 3A) ; the rate of cell proliferation is much higher than that (9%) in CGRP CreER/1 ; ROSA26 mTmG/1 lungs (Fig. 3B) . Proliferating GFP ; ROSA26 mTmG/1 adult mice that had received tamoxifen and naphthalene was calculated. All values are means 6 SEM. *, p < .05; **, p < .01; ***, p < .001; NS, nonsignificant (unpaired Student's t test).
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1 cells continued to express club cell markers and its percentage has also increased. (C'-F'): Immunostaining of lung sections from CGRP CreER/1 ; ROSA26 NICD/mTmG adult mice that had received tamoxifen and naphthalene. By 8 weeks postnaphthalene, PNEC transdifferentiation had reached a steady state and no obvious difference from earlier time points could be discerned. Scale bar 5 25 lm for (A-H); 10 lm for (I-P); 25 lm for (Q-T); 10 lm for (Y-B'). Abbreviation: TM, tamoxifen. and rarely expressed other known lung cell markers (such as CC10) (Fig. 2U-2B weeks post-naphthalene induced lung injury (Fig. 3A) . We noticed that a certain percentage of GFP ; ROSA26 mTmG/1 lungs after TM and naphthalene treatment (Fig. 3C ). This suggests that Notch signaling by itself is insufficient and not required for inducing PNEC proliferation following naphthalene-induced lung injury. However, as described above, Notch pathway activation can synergize with lung injury to promote cell proliferation.
Notch Pathway Activation in Pulmonary Neuroendocrine Cells Fails to Induce Transdifferentiation in the Absence of Lung Injury
Our results suggest that PNECs undergo extensive cell proliferation and transdifferentiation upon Notch pathway activation and lung injury. We wondered whether Notch pathway activation alone is sufficient to promote cell fate change. To test this idea, we injected TM into CGRP CreER/1 ; ROSA26 NICD/lacZ and CGRP CreER/1 ; ROSA26 NICD/mTmG mice to activate Notch signaling (Fig. 5E-5H and data not shown) and followed the fate of lacZ-or GFP-labeled PNECs. We found that all lacZ-or GFPlabeled cells expressed PNEC markers at a level similar to controls and did not express other lung cell markers (Fig. 5I-5L ). For instance, Notch pathway activation failed to reduce Ascl1 levels in mice despite the potent effect of NICD on decreasing Ascl1 levels in cell lines mentioned above (Supporting Information Fig. S2 ). Forced Notch activation also failed to induce PNEC proliferation in the absence of lung injury (Fig. 5M-5P ). This suggests that Notch pathway activation by itself is incapable of inducing cell proliferation or fate change of PNECs during normal homeostasis. This observation also highlights a critical role of lung injury in synergizing with Notch pathway activation during PNEC transdifferentiation.
Expansion and Transdifferentiation of Pulmonary Neuroendocrine Cells in Response to Notch Activation and Lung Injury Are Disrupted by Inactivating EZH2, a Component of the Polycomb Repressive Complex
Molecular machinery that controls epigenetic changes of chromatin contributes to cell differentiation and reprogramming [28] . We reason that it may play an important role in PNEC transdifferentiation. To test this idea, we exploited the polycomb repressive complex 2 (PRC2) [29] and focused on its catalytic component, EZH2 (enhancer of zeste homolog 2). EZH2 is a methyltransferase for histone H3 trimethylation at lysine 27 (H3K27me3). Selective loss of Ezh2 in mouse lung epithelium leads to defects in cell proliferation, airway lineage specification and alveolar formation during embryonic development [30] . In fact, mouse lung epithelium in which Ezh2 is conditionally inactivated lacks terminally differentiated secretory club cells [30] . This led to our hypothesis that EZH2 could mediate PNEC transdifferentiation following lung injury.
We first examined the kinetics of EZH2 expression following epithelial lung injury in wild-type mice in which PNECs were marked by ASCL1 and other markers. While EZH2 expression was low in PNECs of uninjured lungs (Fig. 6A-6D ), its expression in PNECs gradually increased following naphthalene-induced lung injury. At 3 days post-injury, almost all PNECs expressed EZH2 (Fig. 6E-6H ), concomitant with Notch pathway activation in PNECs discussed above. EZH2 immunoreactivity was also detected in other lung epithelial cells, suggesting its functional role in other cell types.
We also checked EZH2 expression in CGRP CreER/1
; ROSA26-NICD/mTmG lungs following TM and naphthalene treatment. While the initial induction of EZH2 followed a time course similar to that of wild-type mice, at 2 weeks post-injury, EZH2 expression was restricted to a small number of GFP 1 cells (Fig. 6I-6L) . Interestingly, cells that still expressed EZH2 were also Ki67 1 (Fig. 6M-6T ). These data corroborate a model in (Fig. 6D') . EPZ-6438 is a potent, selective, and orally bioavailable small-molecule inhibitor of the EZH2 enzymatic activity [31] . Indeed, we found that treatment of SCLC cells derived from CGRP CreER/1 ; p53 f/f ; Rb f/f ; Pten f/f mice [8] with EPZ-6438 led to a drastic reduction in H3K27me3 by Western blotting (data not shown), indicating the effectiveness of EPZ-6438 in inhibiting EZH2 on PNECderived cells. We then examined the consequence of EZH2 inhibition on PNECs transdifferentiation in vivo. CGRP CreER/1 ; ROSA26 NICD/mTmG mice were first injected with TM to activate Notch signaling. EPZ-6438 was then delivered to these mice 1 day before naphthalene-induced lung injury and then every day post-injury. Lungs were analyzed at 2 weeks post-injury. We found that the size of GFP-labeled clusters in the airway of EPZ-6438-treated animals was markedly reduced compared with the vehicle (control) group (Fig. 6U, 6Y, 6C' ), suggesting defective cell proliferation. In addition, ASCL1 expression was lost in the majority of GFP 1 clusters in EPZ-6438-treated lungs (Fig. 6V, 6Z) ; GFP 1 cells in these clusters failed to express other airway epithelial cell markers (Fig. 6W, 6X, 6A', 6B') . These results suggest that inhibition of EZH2 (and PRC2) in PNECs affects their proliferation and transdifferentiation during the injury and repair process.
Activation of the IL6-STAT3 Pathway Is Associated with Transdifferentiation of Pulmonary Neuroendocrine Cells following Lung Injury
Tissue damage triggers inflammation responses, which may potentiate the repair process. To inspect whether inflammatory ; ROSA26 NICD/mTmG adult mice that had received tamoxifen but not naphthalene. While nuclear NICD was induced in GFP-labeled PNECs, none of them underwent fate conversion and expressed other lung cell markers. Moreover, none of the GFP-labeled PNECs incorporated EdU. Scale bar 5 10 lm for (A-D); 7.5 lm for (E-L); 20 lm for (M-P). Abbreviation: TM, tamoxifen. ; ROSA26 NICD/mTmG adult mice that had received tamoxifen and naphthalene. At 2 weeks post-naphthalene, EZH2 was detected in a subset of GFP-labeled cells that also expressed Ki67. (U-C'): Immunostaining and quantification of lung sections from CGRP CreER/1 ; ROSA26 NICD/mTmG adult mice that had received a combination of tamoxifen and naphthalene or a combination of tamoxifen, naphthalene and EZH2 inhibitor EPZ-6438. At 2 weeks post-naphthalene, inhibition of EZH2 led to a reduction in the size of GFP 1 clusters, most of which (>85%) also failed to express epithelial lung cell markers. (D'): Schematic diagram showing sequential treatment with tamoxifen, EPZ-6438 and naphthalene. All values are means 6 SEM. *, p < .05; **, p < .01; ***, p < .001; NS, nonsignificant (unpaired Student's t test). Scale bar 5 25 lm for (A-B') . Abbreviation: TM, tamoxifen. responses are involved in PNEC transdifferentiation, we examined inflammatory cytokines in the lungs at different time points following naphthalene-induced lung injury. Interestingly, a transient 30-fold increase in Interleukin 6 (Il6) transcript levels was detected at 12 hours post-injury compared with the steady state and returned to basal levels at approximately 72 hours post-injury (Fig. 7A) . By contrast, the transcript levels of Il1b, Il4 and Il17 were only mildly elevated at 24 hours post-injury while Tnfa levels were unaltered (Fig. 7A) . Scgb1a1 (CC10) expression levels quickly dropped to 40% at 12 hours following injury and almost disappeared 24 hours later (Fig. 7A) , indicating efficient killing of club cells by naphthalene.
IL6 binds its receptors to trigger a signaling cascade that leads to phosphorylation of signal transducer and activator of transcription 3 (STAT3) by Janus kinases (JAKs). Phospho-STAT3 (p-STAT3) translocates to the nucleus to transcriptionally activate target genes. We next asked whether the IL6/STAT3 pathway is activated in vivo in response to lung injury. Expression of p-STAT3 was significantly upregulated as early as 6 hours after naphthalene administration by Western blot analysis of whole-lung lysates from wild-type mice and declined 72 hours later (Fig. 7B) . Similarly, upregulation of p-STAT3 in the airway epithelium of CGRP CreER/1 ; ROSA26 mTmG/1 mice, including almost all PNECs, was apparent by 24 hours post-injury by immunohistochemistry and p-STAT3 levels dropped 72 hours later (Fig. 7C-F) . p-STAT3 upregulation was correlated with Il6 expression. By contrast, p-AKT and p-ERK levels were largely unchanged after lung injury (data not shown). These observations uphold a potential role of the IL6-STAT3 pathway in PNEC transdifferentiation in response to lung injury. Interestingly, the kinetics of EZH2 and p-STAT3 expression were unaffected by the loss of Rbpj (Supporting Information Fig. S3 ), suggesting that EZH2 and IL6-STAT3 function in parallel to Notch signaling.
Hedgehog Signaling or Hippo Signaling Has No Apparent Effects on Fate Change of Pulmonary Neuroendocrine Cells Following Lung Injury
We also studied whether major signaling pathways other than the Notch pathway could influence the PNEC fate following lung injury. We tested the Hedgehog (Hh) pathway since Hh signaling has been associated with SCLC development [32, 33] and PNECs can be the tumor-initiating cells of SCLC [7] [8] [9] . We generated CGRP CreER/1 ; ROSA26 SMOM2/lacZ and CGRP CreER/1 ; ROSA26 SMOM2/mTmG mice, which carry the ROSA26 SMOM2 allele [34] in addition to a lacZ or GFP reporter allele, respectively, and administered TM to induce SMOM2 expression in PNECs. This was again followed by naphthalene administration to Fig. S4  and data not shown) . Hence, Hh pathway activation failed to affect the process of PNEC proliferation and fate change following lung injury.
In addition to Hh signaling, we investigated the potential role of Hippo signaling in controlling PNEC transdifferentiation following lung injury. We previously showed that YAP, the transcriptional coactivator and key executer of Hippo signaling, regulates cell number and mechanical force production during lung branching morphogenesis [36] . Moreover, consistent with a possible role of YAP in controlling PNEC transdifferentiation, nuclear (active) YAP was detected in GFP-labeled cells in CGRP CreER/1 ; ROSA26 NICD/mTmG lungs at 3 days post-injury (Supporting Information Fig. S5 ). This prompted us to test whether YAP could influence PNEC transdifferentiation. To this end, we generated CGRP Fig. S5 ). Together, these findings on major signaling pathways underscore a unique role of Notch signaling in controlling PNEC transdifferentiation following lung injury.
DISCUSSION
Our studies identify Notch signaling as an essential mechanism in controlling the PNEC fate following lung injury (Fig.  7G ). This suggests that Notch signaling regulates the cell fate of PNECs both during embryonic development and following injury/repair. Our finding also supports the notion that major signaling pathways that control cell fate determination during development are activated in response to injury and instruct cell fate change. We anticipate that Notch signaling interacts with other pathways in mediating PNEC transdifferentiation. Our system thus provides a unique opportunity to investigate the molecular basis of PNEC fate change in physiological and pathological settings.
Notch activation and lung injury are both required to induce massive cell expansion and fate change of PNECs. It is unclear how Notch activation and lung injury interact to control cell expansion and fate change. Without the knowledge of the signals received by PNECs due to lung injury, it is difficult to discern the responses in PNECs. Moreover, how cell expansion and fate change are coordinately regulated is unclear. These key issues can only be resolved by molecular studies that discover the events downstream of Notch activation and lung injury, respectively.
Following Notch activation and lung injury, many airways in CGRP CreER/1 ; ROSA26 NICD/lacZ or CGRP CreER/1 ; ROSA26 NICD/mTmG mice contained close to 50% of PNEC-derived cells. These animals did not display gross abnormalities, consistent with the ability of lungs to maintain physiological function despite substantial structural defects of the lungs inflicted by injury. It is possible that phenotypes will appear in CGRP CreER/1 ; ROSA26 NICD/lacZ or CGRP CreER/1 ; ROSA26 NICD/mTmG mice upon various challenges to these animals. These studies will reveal the properties of these PNEC-derived cells and their roles in lung pathology.
Our model of lung injury focuses on naphthalene-induced lung damage. It would be essential to explore how PNECs respond to other types of insults such as influenza viral infection. It is possible that different types of insult induce distinct responses or similar responses but via different molecular mechanisms. Results from these investigations will greatly enhance our mechanistic understanding of lung injury and repair and form the basis of therapies by harnessing the regenerative potential of various cell types.
Interestingly, our study established a connection between PNEC transdifferentiation and epigenetic modification mediated by the PRC2 complex and inflammatory responses that involve the IL6-STAT3 pathway. Both the PRC2 complex and the IL6-pSTAT3 pathway could potentially mediate or interact with the Notch pathway in promoting transdifferentiation. While epigenetic changes mediated by PRC2 have been implicated in fate determination during homeostasis and in cancer development [29, 38, 39] , its role in lung injury/repair has not been investigated. Our work established an important connection between PRC2 and PNEC transdifferentiation, opening up a new chapter in understanding the molecular basis of cell fate determination during injury/repair. It is important to point out that the IL6-STAT3 pathway has been shown to promote regeneration of airway ciliated cells from basal cells [40] . Establishing the functional role of IL6-STAT3 in PNEC transdifferentiation will provide key insight into the relationship between inflammatory responses, signaling pathways and fate change in response to lung injury.
While Notch signaling controls the PNEC fate following lung injury, neither Hh nor Hippo signaling seems to exert noticeable effects on PNECs in a similar experimental setting. This is somewhat unexpected given that major signaling pathways control cell expansion in many tissues following injury. Perhaps, it reflects the unique response of each cell type to injury. This argues that studies conducted on individual cell types in a given organ are required to reveal the molecular mechanisms of cell expansion and transdifferentiation.
Our findings suggest that active Notch signaling in injured lung epithelium can direct PNEC transdifferentiation. This implies that altered lung cell fates likely contribute to the pathogenesis of human lung diseases. In fact, several lung diseases with altered PNECs have been reported [4] and it would be interesting to determine whether a subset of them are associated with abnormal Notch signaling or alterations in other signaling pathways. Moreover, our animal studies could facilitate the identification of genes and pathways that function downstream of the Notch pathway. They can also reveal the source of Notch ligands or signals that trigger Notch pathway activation. These investigations could offer new diagnosis and/or treatment of human lung diseases related to aberrant Notch signaling. More broadly, they have important implications for understanding human lung diseases caused by aberrant signaling and fate alteration. Among the major signaling pathways, Notch signaling is a pivotal player in cell fate decision during embryonic development. Disruption of Notch signaling during lung development results in a dramatic loss of secretory club cells and correspondingly, an increased number of ciliated cells [15, 16] . Moreover, downregulation of Notch signaling is known to promote the PNEC fate [15, 17, 18] while sustained Notch signaling in developing lungs compromised PNEC generation [19] . These findings suggest that Notch signaling promotes differentiation toward the club cell fate while inhibiting the production of PNECs and ciliated cells during development. By contrast, high levels of Notch activity appear to drive goblet cell identity at the expense of ciliated cells during lung development [20] . These and other findings support a model in which Notch signaling is a major determinant in regulating cell-cell communication and cell fate decision during lung development. Consistent with deployment of developmental pathways for tissue repair and regeneration, Notch signaling is involved in fate determination of basal cells [41] , club cell regeneration [42] or PNEC transdifferentiation (this study) following lung injury. These observations suggest that Notch signaling likely controls the fate of other lung cell types in response to various lung insults or cell types in other organs that have not been studied. Recently, Notch activation in SCLC was shown to direct neuroendocrine to nonneuroendocrine fate switch [43] . This is in contrast to the inability of Notch activation in PNECs to confer new fates in the absence of lung injury. It suggests that small cell lung tumor cells are in a different cell state from PNECs and are primed for fate change. Future comparative transcriptome analysis will provide additional insight into this important issue. Interestingly, the switch to non-neuroendocrine SCLC cells was mediated in part by Rest while Ascl1 knockdown by itself had no apparent effect. It would be interesting to test the effects of Ascl1 and Rest in PNEC transdifferentiation following lung injury. Thus, while fate change induced by Notch activation is a universal phenomenon, the cellular state and context collectively influence how Notch signaling directs the transition to a new cell fate.
CONCLUSION
Our findings uncovered Notch signaling as a key determinant in controlling PNEC transdifferentiation following lung injury. Our study also revealed the involvement of epigenetic modification and inflammatory responses in PNEC fate conversion. These results provide a new framework for studying the molecular mechanism of PNEC transdifferentiation. We anticipate that these investigations will have general implications for understanding lineage conversion of other cell types and hold promise for regenerative medicine.
